Abstract
Rheumatoid arthritis (RA) is a common and debilitating disease. Expanded therapeutic options, targeting pro-inflammatory cytokines such as tumour necrosis factor (TNF) and interleukin-6 (IL-6), have revolutionised RA treatment. To date, efficacy data shows superiority of IL-6 inhibition over placebo, conventional disease modifying anti-rheumatic drugs such as methotrexate, and TNF inhibition. Moreover, while demonstrating some key differences in the safety profile compared with TNF inhibition (e.g. hyperlipidemia and neutropenia), these safety concerns have not, at least to date, been found to cause clinically significant adverse outcomes. Other safety parameters, such as infection and malignancy rates have been found to be comparable between IL-6 and TNF inhibition. This review explores the biology and clinical applications of IL-6 inhibition in the management of RA.
Keywords: Rheumatoid arthritis, interleukin-6, treatment, inflammation.
Current Pharmaceutical Design
Title:Interleukin-6 In Rheumatoid Arthritis - From The Laboratory To The Bedside
Volume: 21 Issue: 17
Author(s): Xiao Liu, Andrew J. Teichtahl and Ian P. Wicks
Affiliation:
Keywords: Rheumatoid arthritis, interleukin-6, treatment, inflammation.
Abstract: Rheumatoid arthritis (RA) is a common and debilitating disease. Expanded therapeutic options, targeting pro-inflammatory cytokines such as tumour necrosis factor (TNF) and interleukin-6 (IL-6), have revolutionised RA treatment. To date, efficacy data shows superiority of IL-6 inhibition over placebo, conventional disease modifying anti-rheumatic drugs such as methotrexate, and TNF inhibition. Moreover, while demonstrating some key differences in the safety profile compared with TNF inhibition (e.g. hyperlipidemia and neutropenia), these safety concerns have not, at least to date, been found to cause clinically significant adverse outcomes. Other safety parameters, such as infection and malignancy rates have been found to be comparable between IL-6 and TNF inhibition. This review explores the biology and clinical applications of IL-6 inhibition in the management of RA.
Export Options
About this article
Cite this article as:
Liu Xiao, Teichtahl J. Andrew and Wicks P. Ian, Interleukin-6 In Rheumatoid Arthritis - From The Laboratory To The Bedside, Current Pharmaceutical Design 2015; 21 (17) . https://dx.doi.org/10.2174/1381612821666150310143332
DOI https://dx.doi.org/10.2174/1381612821666150310143332 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Stem Cells in Pharmaceutical Biotechnology
Current Pharmaceutical Biotechnology Opioid Receptors and Their Ligands in the Musculoskeletal System and Relevance for Pain Control
Current Pharmaceutical Design T-Cell-Mediated Signalling in Immune, Inflammatory and Angiogenic Processes: The Cascade of Events Leading to Inflammatory Diseases
Current Drug Targets - Inflammation & Allergy Trends in the Exploration of Anticancer Targets and Strategies in Enhancing the Efficacy of Drug Targeting
Current Molecular Pharmacology MMP-2 Selectivity in Hydroxamate-Type Inhibitors
Current Medicinal Chemistry Chymase Inhibitors
Current Pharmaceutical Design Drug Discovery and Protein Tyrosine Phosphatases
Current Medicinal Chemistry Modulation of T Cell Proliferation Through the LIGHT-HVEM-BTLA Cosignaling Pathway
Recent Patents on DNA & Gene Sequences Destroying RNA as a Therapeutic Approach
Current Medicinal Chemistry Methionine Aminopeptidases as Potential Targets for Treatment of Gastrointestinal Cancers and other Tumors
Current Drug Targets A Concise Update on the Relevance of Secretory Phospholipase A2 Group IIA and its Inhibitors with Cancer
Medicinal Chemistry Chemical Space of FLT3 Inhibitors as Potential Anti-AML Drugs
Recent Patents on Anti-Cancer Drug Discovery Natural Products as Promising Drug Candidates for the Treatment of Alzheimer’s Disease: Molecular Mechanism Aspect
Current Neuropharmacology The Gender Bender effect in Periodontal Immune Response
Endocrine, Metabolic & Immune Disorders - Drug Targets Recent Patents on Metalloproteinases as Biomarkers in Osteoarthritis Diagnosis and Treatment
Recent Patents on Biomarkers Contribution of Dietary Factors to Peroxisome Proliferator-Activated Receptor-Mediated Inflammatory Signaling in Arthritic Diseases
Current Rheumatology Reviews Autophagy Modulators and Neuroinflammation
Current Medicinal Chemistry Review: New Anti-Cytokines for IBD: What is in the Pipeline?
Current Drug Targets Anti-Angiogenic Therapy as a Cancer Treatment Paradigm
Current Medicinal Chemistry - Anti-Cancer Agents From Laptop to Benchtop to Bedside: Structure-based Drug Design on Protein Targets
Current Pharmaceutical Design